Jazz Pharmaceuticals (JAZZ) on Monday reported long-term survival results from a phase 2 trial evaluating its investigational HER2-targeted therapy Ziihera in combination with chemotherapy as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma.
The company said median overall survival reached 36.5 months among the 46 enrolled patients, with a median progression-free survival of 12.5 months. In the subgroup of 41 patients with centrally confirmed HER2-positive tumors, median progression-free survival was 15.2 months.
The data was presented at the American Society of Clinical Oncology annual meeting.
A Phase 3 trial evaluating Ziihera in the same indication is ongoing, with top-line results expected in the second half of 2025, Jazz said.
Price: 108.84, Change: +0.77, Percent Change: +0.71
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.